Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinphar Pharmaceutical Co (TPE:1734) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sinphar Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$6,933 Mil.
Sinphar Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$439 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co EV-to-EBIT Related Terms
Sinphar Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1734 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Sinphar Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinphar Pharmaceutical Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinphar Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sinphar Pharmaceutical Co's EV-to-EBIT falls into.
Sinphar Pharmaceutical Co's current Enterprise Value is NT$7,295 Mil.
Sinphar Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$439 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinphar Pharmaceutical Co (TPE:1734) has a EV-to-EBIT of 16.63 as of Aug. 28, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sinphar Pharmaceutical Co and its competitors. This is near median its historical median of 15.93. According to the industry distribution chart, Sinphar Pharmaceutical Co ranks #195 out of 380 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Sinphar Pharmaceutical Co's EV-to-EBIT too high?
Sinphar Pharmaceutical Co's current EV-to-EBIT of 16.63 is near median its 10-year median of 15.93. The Biotechnology industry median EV-to-EBIT is 15.92. Sinphar Pharmaceutical Co's value of 16.63 is 4.5% above this industry median. Based on the distribution chart, Sinphar Pharmaceutical Co ranks #195 out of 380 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sinphar Pharmaceutical Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sinphar Pharmaceutical Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinphar Pharmaceutical Co ranks #195 out of 380 companies for EV-to-EBIT. This places Sinphar Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 15.92. Sinphar Pharmaceutical Co's value of 16.63 is 4.5% above this benchmark. While the company's 10-year median is 15.93 vs. the industry median of 15.92, Sinphar Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.92, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinphar Pharmaceutical Co's current EV-to-EBIT of 16.63 is 4.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sinphar Pharmaceutical Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinphar Pharmaceutical Co's current EV-to-EBIT is 16.63, which is near median its own 10-year median of 15.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinphar Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co (TPE:1734) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.89, compared to a current price of NT$30.75 — trading 2.9% above its estimated fair value. The current EV-to-EBIT is 16.63, which is near median its 10-year median of 15.93 and 4.5% above the Biotechnology industry median of 15.92. Sinphar Pharmaceutical Co's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sinphar Pharmaceutical Co (TPE:1734), the current EV-to-EBIT is 16.63 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinphar Pharmaceutical Co (TPE:1734) Overvalued in 2026?
Based on GuruFocus' analysis, Sinphar Pharmaceutical Co stock appears to be overvalued.
The current stock price of NT$30.75 is trading 2.9% above its estimated GF Value™ of NT$29.89.
GuruFocus considers Sinphar Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TPE:1734:
EV-to-EBIT: 16.63 (near median its 10-year median of 15.93)
GF Value™: NT$29.89 vs. price of NT$30.75 (2.9% above fair value)
Industry Position: 4.5% above the Biotechnology median (#195 of 380)
No single metric tells the full story. See the TPE:1734 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinphar Pharmaceutical Co Ltd operates in the pharmaceutical segment. The company mainly engages in the production, processing, and trading of various Chinese medicines, medicinal cosmetics, and nutrients. The company's reportable segments are; Pharmaceuticals which derives key revenue, Healthy food, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from China, Vietnam, Indonesia, America, and other regions.
82GF Score
Get the complete analysis for TPE:1734
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1734 has been successfully added to your 
